^
    Back
    Association details:
    Biomarker:ER positive
    Cancer:Endometrial Cancer
    Drug Class:CDK4 inhibitor +
    CDK6 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    IGCS 2023
    Title:

    EVALUATING CDK 4/6 INHIBITORS IN COMBINATION WITH ENDOCRINE THERAPY IN ENDOMETRIAL CANCERS: A RETROSPECTIVE STUDY

    Published date:
    10/18/2023
    Excerpt:
    Patients with ER+EC have reasonable responses to CDK4/6i+ET...This data supports the findings from the previously published clinical trials that CDK4/6i+ET should be considered as a treatment option in recurrent ER+EC.
    Secondary therapy:
    Hormone Therapy
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESGO 2023
    Title:

    755 - Evaluating The Combination Of CDK 4/6 Inhibitors And Endocrine Therapy In Endometrial And Ovarian Cancers: A Retrospective Study.

    Published date:
    09/18/2023
    Excerpt:
    The purpose of this study is to evaluate characteristics and clinical outcomes of patients with ER+ EC or ovarian cancer (OC) who have received a CDK4/6i+ET at our institution....For EC patients who started CDK4/6i+ET concurrently, their DOR was 11.7 months (IQR 7.7-24 months) with BRR of partial response (PR) (n=1), SD (n=2), and progressive disease (n=3). For OC, the TTF was 13.5 months (95% CI 5.4-not evaluable). All OC patients had CDK 4/6i added to their ET due to progression, with a median DOR on CDK4/6i+ET of 9.0 months (IQR 5.4-13.5 months).
    Secondary therapy:
    Hormone Therapy